Camzoy 5 mg, manufactured by Beacon Pharmaceuticals, contains Mavacamten—a cardiac myosin inhibitor used in the treatment of obstructive hypertrophic cardiomyopathy (oHCM). It improves heart function by reducing excessive contraction of the heart muscle, thereby lowering left ventricular outflow tract (LVOT) obstruction. Recommended for patients with NYHA Class II–III symptoms, Camzoy helps reduce shortness of breath, chest pain, and fatigue.